The interventional oncology market valued at US$ 2.53 Billion in 2023, is forecasted to grow at a robust CAGR of 9.0%, reaching US$ 2.75 Billion in 2024 and an impressive US$ 4.24 Billion by 2029. The ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Medtronic introduced a next-generation cryoablation system designed for enhanced tumor targeting and patient outcomes. Statistical Insights .Approximately 20 million new cancer cases were reported ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Unlike conventional radiofrequency ablation and cryoablation for atrial fibrillation ... the first PFA system to receive FDA approval, Medtronic's PulseSelect PFA system, which has been approved ...

First-in-human studies are scheduled for 2021.46 47 Radiofrequency ablation (RFA) with the Barrx device (Medtronic, Dublin ... available data for use in the oesophagus are still limited. Cryoablation ...

Medtronic is a solid dividend-paying stock. Its stock recently yielded 3.2%. It has increased its payout for nearly 50 years in a row. If you're a dividend investor, I can understand why ...

In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against the other AI stocks. In the third quarter of 2024, investment titan Blackrock released a commentary on ...